Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.41 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589355 | 0.91 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL22589283 | 0.90 | CHRM2 (0.51) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL6950463 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL7672577 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL3099573 | 0.83 | CHRM2 (0.54) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2C19 | |
| SCHEMBL5117324 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL5117318 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL22589174 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL7679543 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9AGRIN2BCYP2D6 | |
| SCHEMBL9256664 | 0.77 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2020219591-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-1278520-B1 | DIARYL PIPERIDYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS | MERCK & CO INC (US) | 2006-03-01 | — | — | EP | disclosed |
| US-6528531-B1 | Coccidiosis in poultry; | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-6432980-B1 | PREVENTION OF COCCIDIOSIS IN POULTRY | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-6291480-B1 | CONTROL OF COCCIDIOSIS IN POULTRY. | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001034150-A1 | ALIPHATIC AMINE SUBSTITUTED PIPERIDYL DIARYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS | MERCK & CO., INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | REN, FURIN, QTRT1 | SMN1; SMN2 207/4885NPC1 175/4885RAB9A 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.